Complement 1 Raises $16M to Scale Evidence-Based Lifestyle Medicine Platform for Cancer Care
Complement 1, a U.S.-based health technology startup founded in 2024, has announced a $16 million oversubscribed seed funding round led by Owl Ventures and Blume Ventures. The company is emerging from stealth with a tech-enabled, clinically validated lifestyle modification platform designed for cancer patients and high-risk individuals.
The platform offers personalized, daily guidance through one-on-one support from dedicated CoActive Coaches, focusing on evidence-based interventions in physical activity, nutrition, and somatic practices. Built on extensive meta-analyses and clinical trials, the program has shown significant benefits, including 37% fewer treatment side effects, 18% less pain, 27% improved sleep, and over 90% program adherence rates among users.
Complement 1’s approach uses a medically validated rule engine to tailor interventions based on each individual’s cancer type, treatment stage, side-effect profile, and personal preferences. The programs are aligned with leading oncology guidelines, including those from the American Institute for Cancer Research, ensuring both relevance and clinical rigor.
The funding will be used to scale the company’s operations, advance its AI-driven personalization engine, deepen partnerships with cancer centers and healthcare providers, and enhance the digital user experience for both patients and coaches. Early modeling suggests that Complement 1’s approach could reduce healthcare costs by 30% across cancer and high-risk populations through improved lifestyle adherence.
“Every oncologist understands the value of lifestyle change in improving patient outcomes, but implementation has remained a challenge,” noted Karan Bajaj, CEO and Co-Founder. “Complement 1 addresses this gap through high-tech, high-touch coaching that patients can realistically engage with throughout their treatment journey.”
With strong clinical validation, high patient engagement, and significant investor backing, Complement 1 is positioned to transform cancer care delivery by empowering patients through holistic, evidence-based lifestyle interventions.
